Tweet
Sci Adv
. 2024 Apr 12;10(15):eadl4393.
doi: 10.1126/sciadv.adl4393. Epub 2024 Apr 10. Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera
Yuanqin Min 1 , Wei Xiong 2 , Wei Shen 2 , Xingyu Liu 2 , Qianqian Qi 2 , Yuanyuan Zhang 2 , Ruochen Fan 2 , Fang Fu 2 , Heng Xue 1 , Hang Yang 1 , Xiulian Sun 1 , Yunjia Ning 1 , Tian Tian 2 , Xiang Zhou 2
Affiliations
In response to the urgent need for potent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapeutics, this study introduces an innovative nucleoside tailoring strategy leveraging ribonuclease targeting chimeras. By seamlessly integrating ribonuclease L recruiters into nucleosides, we address RNA recognition challenges and effectively inhibit severe acute respiratory syndrome coronavirus 2 replication in human cells. Notably, nucleosides tailored at the ribose 2'-position outperform those modified at the nucleobase. Our in vivo validation using hamster models further bolsters the promise of this nucleoside tailoring approach, positioning it as a valuable asset in the development of innovative antiviral drugs.
. 2024 Apr 12;10(15):eadl4393.
doi: 10.1126/sciadv.adl4393. Epub 2024 Apr 10. Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera
Yuanqin Min 1 , Wei Xiong 2 , Wei Shen 2 , Xingyu Liu 2 , Qianqian Qi 2 , Yuanyuan Zhang 2 , Ruochen Fan 2 , Fang Fu 2 , Heng Xue 1 , Hang Yang 1 , Xiulian Sun 1 , Yunjia Ning 1 , Tian Tian 2 , Xiang Zhou 2
Affiliations
- PMID: 38598625
- DOI: 10.1126/sciadv.adl4393
In response to the urgent need for potent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapeutics, this study introduces an innovative nucleoside tailoring strategy leveraging ribonuclease targeting chimeras. By seamlessly integrating ribonuclease L recruiters into nucleosides, we address RNA recognition challenges and effectively inhibit severe acute respiratory syndrome coronavirus 2 replication in human cells. Notably, nucleosides tailored at the ribose 2'-position outperform those modified at the nucleobase. Our in vivo validation using hamster models further bolsters the promise of this nucleoside tailoring approach, positioning it as a valuable asset in the development of innovative antiviral drugs.